High-mobility group box-1 and endothelial cell angiogenic markers in the vitreous from patients with proliferative diabetic retinopathy

Mediators of Inflammation

Volumn 2012, Issue , 2012, Pages

  Abu El Asrar, Ahmed M ^a,b   Nawaz, Mohd Imtiaz ^a   Kangave, Dustan ^a   Abouammoh, Marwan ^a   Mohammad, Ghulam ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOGLIN; GRANULOCYTE COLONY STIMULATING FACTOR; HIGH MOBILITY GROUP B1 PROTEIN; VASCULAR ENDOTHELIAL CADHERIN; BIOLOGICAL MARKER; CADHERIN; LEUKOCYTE ANTIGEN; VASCULOTROPIN A;

ANGIOGENESIS; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC RETINOPATHY; DISEASE ACTIVITY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETINA DETACHMENT; TREATMENT INDICATION; VITRECTOMY; VITREOUS BODY; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); STATISTICAL MODEL;

ANTIGENS, CD; BIOLOGICAL MARKERS; CADHERINS; DIABETIC RETINOPATHY; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HMGB1 PROTEIN; HUMANS; LOGISTIC MODELS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 84869021626     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2012/697489     Document Type: Article

References (50)

1. Spranger J., Pfeiffer A. F. H., New concepts in pathogenesis and treatment of diabetic retinopathy. Experimental and Clinical Endocrinology and Diabetes 2001 109 2 S438 S450 2-s2.0-0034948833 10.1055/s-2001-18601 (Pubitemid 32586079)
2. Joussen A. M., Poulaki V., Le M. L., Koizumi K., Esser C., Janicki H., Schraermeyer U., Kociok N., Fauser S., Kirchhof B., Kern T. S., Adamis A. P., A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB Journal 2004 18 12 1450 1452 2-s2.0-7044228789 10.1096/fj.03-1476fje (Pubitemid 39561611)
3. Miyamoto K., Khosrof S., Bursell S. E., Rohan R., Murata T., Clermont A. C., Aiello L. P., Ogura Y., Adamis A. P., Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proceedings of the National Academy of Sciences of the United States of America 1999 96 19 10836 10841 2-s2.0-0032863021 10.1073/pnas.96.19.10836 (Pubitemid 29442230)
4. Abu El-Asrar A. M., Struyf S., Kangave D., Geboes K., Van Damme J., Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. European Cytokine Network 2006 17 3 155 165 2-s2.0-39049193307
5. Abu El-Asrar A. M., Missotten L., Geboes K., Expression of cyclo-oxygenase-2 and downstream enzymes in diabetic fibrovascular epiretinal membranes. British Journal of Ophthalmology 2008 92 11 1534 1539 2-s2.0-55449103992 10.1136/bjo.2008.142182
6. van Beijnum J. R., Buurman W. A., Griffioen A. W., Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis 2008 11 1 91 99 2-s2.0-41049117932 10.1007/s10456-008-9093-5
7. Treutiger C. J., Mullins G. E., Johansson A. S. M., Rouhiainen A., Rauvala H. M. E., Erlandsson-Harris H., Andersson U., Yang H., Tracey K. J., Andersson J., Palmblad J. E. W., High mobility group 1 B-box mediates activation of human endothelium. Journal of Internal Medicine 2003 254 4 375 385 2-s2.0-0141750710 10.1046/j.1365-2796.2003.01204.x (Pubitemid 37211261)
8. Fiuza C., Bustin M., Talwar S., Tropea M., Gerstenberger E., Shelhamer J. H., Suffredini A. F., Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003 101 7 2652 2660 2-s2.0-0037769813 10.1182/blood-2002-05-1300 (Pubitemid 36857626)
9. Luan Z. G., Zhang H., Yang P. T., Ma X. C., Zhang C., Guo R. X., HMGB1 activates nuclear factor- κ B signaling by RAGE and increases the production of TNF- α in human umbilical vein endothelial cells. Immunobiology 2010 215 12 956 962 2-s2.0-78049291345 10.1016/j.imbio.2009.11.001
10. van Beijnum J. R., Nowak-Sliwinska P., van den Boezem E., Hautvast P., Buurman W. A., Griffioen A. W., Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1. Oncogene. In press 10.1038/onc.2012.49
11. Mitola S., Belleri M., Urbinati C., Coltrini D., Sparatore B., Pedrazzi M., Melloni E., Presta M., Cutting edge: Extracellular high mobility group box-1 protein is a proangiogenic cytokine. Journal of Immunology 2006 176 1 12 15 2-s2.0-29644441337 (Pubitemid 43023243)
12. Schlueter C., Weber H., Meyer B., Rogalla P., Röser K., Hauke S., Bullerdiek J., Angiogenetic signaling through hypoxia HMGB1: an angiogenetic switch molecule. American Journal of Pathology 2005 166 4 1259 1263 2-s2.0-17144400438 (Pubitemid 40524448)
13. Chavakis E., Hain A., Vinci M., Carmona G., Bianchi M. E., Vajkoczy P., Zeiher A. M., Chavakis T., Dimmeler S., High-mobility group box 1 activates integrin-dependent homing of endothelial progenitor cells. Circulation Research 2007 100 2 204 212 2-s2.0-33846844786 10.1161/01.RES.0000257774.55970.f4 (Pubitemid 46208720)
14. Van Beijnum J. R., Dings R. P., Van Der Linden E., Zwaans B. M. M., Ramaekers F. C. S., Mayo K. H., Griffioen A. W., Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. Blood 2006 108 7 2339 2348 2-s2.0-33749332105 10.1182/blood-2006- 02-004291 (Pubitemid 44497518)
15. El-Asrar A. M. A., Missotten L., Geboes K., Expression of high-mobility groups box-1/receptor for advanced glycation end products/osteopontin/early growth response-1 pathway in proliferative vitreoretinal epiretinal membranes. Molecular Vision 2011 17 508 518 2-s2.0-79952145525
16. El-Asrar A. M. A., Nawaz M. I., Kangave D., Geboes K., Ola M. S., Ahmad S., Al-Shabrawey M., High-mobility group box-1 and biomarkers of inflammation in the vitreous from patients with proliferative diabetic retinopathy. Molecular Vision 2011 17 1829 1838 2-s2.0-79960729070
17. Vestweber D., VE-cadherin: the major endothelial adhesion molecule controlling cellular junctions and blood vessel formation. Arteriosclerosis, Thrombosis, and Vascular Biology 2008 28 2 223 232 2-s2.0-38549128935 10.1161/ATVBAHA.107.158014 (Pubitemid 351161193)
18. Harris E. S., Nelson W. J., VE-cadherin: at the front, center, and sides of endothelial cell organization and function. Current Opinion in Cell Biology 2010 22 5 651 658 2-s2.0-77957233298 10.1016/j.ceb.2010.07.006
19. Wrobel T., Mazur G., Wolowiec D., Jazwiec B., Sowinska E., Kuliczkowski K., sVE-cadherin and sCD146 serum levels in patients with multiple myeloma. Clinical and Laboratory Haematology 2006 28 1 36 39 2-s2.0-33645051735 10.1111/j.1365-2257.2006.00756.x
20. Rabascio C., Muratori E., Mancuso P., Calleri A., Raia V., Foutz T., Cinieri S., Veronesi G., Pruneri G., Lampertico P., Iavarone M., Martinelli G., Goldhirsch A., Bertolini F., Assessing tumor angiogenesis: increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells. Cancer Research 2004 64 12 4373 4377 2-s2.0-3042523515 10.1158/0008-5472.CAN-04-0265 (Pubitemid 38802446)
21. Sidibé A., Mannic T., Arboleas M., Subileau M., Gulino-Debrac D., Bouillet L., Jan M., Vandhuick T., Le Loët X., Vittecoq O., Vilgrain I., Soluble VE-cadherin in rheumatoid arthritis patients correlates with disease activity: evidence for tumor necrosis factor α -induced VE-cadherin cleavage. Arthritis and Rheumatism 2012 64 1 77 87 2-s2.0-84855274887 10.1002/art.33336
22. Soeki T., Tamura Y., Shinohara H., Sakabe K., Onose Y., Fukuda N., Elevated concentration of soluble vascular endothelial cadherin is associated with coronary atherosclerosis. Circulation Journal 2004 68 1 1 5 2-s2.0-0942266125 10.1253/circj.68.1 (Pubitemid 38139928)
23. Habibagahi Z., Habibagahi M., Heidari M., Raised concentration of soluble form of vascular endothelial cadherin and IL-23 in sera of patients with Behet's disease. Modern Rheumatology 2010 20 2 154 159 2-s2.0-77954758833 10.1007/s10165-009-0246-1
24. Villasante A., Pacheco A., Pau E., Ruiz A., Pellicer A., Garcia-Velasco J. A., Soluble vascular endothelial-cadherin levels correlate with clinical and biological aspects of severe ovarian hyperstimulation syndrome. Human Reproduction 2008 23 3 662 667 2-s2.0-40749092864 10.1093/humrep/dem429 (Pubitemid 351651225)
25. Shih S. C., Robinson G. S., Perruzzi C. A., Calvo A., Desai K., Green J. E., Ali I. U., Smith L. E. H., Senger D. R., Molecular profiling of angiogenesis markers. American Journal of Pathology 2002 161 1 35 41 2-s2.0-0036310275 (Pubitemid 34760768)
26. Ten Dijke P., Goumans M. J., Pardali E., Endoglin in angiogenesis and vascular diseases. Angiogenesis 2008 11 1 79 89 2-s2.0-41049094560 10.1007/s10456-008-9101-9
27. Duff S. E., Li C., Garland J. M., Kumar S., CD105 is important for angiogenesis: evidence and potential applications. FASEB Journal 2003 17 9 984 992 2-s2.0-0038725471 10.1096/fj.02-0634rev (Pubitemid 36676386)
28. Li C., Guo B., Wilson P. B., Stewart A., Byrne G., Bundred N., Kumar S., Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer. International Journal of Cancer 2000 86 3 122 126 2-s2.0-0034688954 (Pubitemid 30185919)
29. Masuyama H., Nakatsukasa H., Takamoto N., Hiramatsu Y., Correlation between soluble endoglin, vascular endothelial growth factor receptor-1, and adipocytokines in preeclampsia. Journal of Clinical Endocrinology and Metabolism 2007 92 7 2672 2679 2-s2.0-34447122605 10.1210/jc.2006-2349 (Pubitemid 47037375)
30. Hawinkels L. J. A. C., Kuiper P., Wiercinska E., Verspaget H. W., Liu Z., Pardali E., Sier C. F. M., Ten Dijke P., Matrix metalloproteinase-14 (MT1-MMP)-mediated endoglin shedding inhibits tumor angiogenesis. Cancer Research 2010 70 10 4141 4150 2-s2.0-77952828002 10.1158/0008-5472.CAN-09-4466
31. Castonguay R., Werner E. D., Matthews R. G., Presman E., Mulivor A. W., Solban N., Sako D., Pearsall R. S., Underwood K. W., Seehra J., Kumar R., Grinberg A. V., Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth. Journal of Biological Chemistry 2011 286 34 30034 30046 2-s2.0-80051920312 10.1074/jbc.M111.260133
32. Lee S. T., Chu K., Jung K. H., Ko S. Y., Kim E. H., Sinn D. I., Lee Y. S., Lo E. H., Kim M., Roh J. K., Granulocyte colony-stimulating factor enhances angiogenesis after focal cerebral ischemia. Brain Research 2005 1058 1-2 120 128 2-s2.0-26244442250 10.1016/j.brainres.2005.07.076 (Pubitemid 41416806)
33. Ohki Y., Heissig B., Sato Y., Akiyama H., Zhu Z., Hicklin D. J., Shimada K., Ogawa H., Daida H., Hattori K., Ohsaka A., Granulocyte colony-stimulating factor promotes neovascularization by releasing vascular endothelial growth factor from neutrophils. FASEB Journal 2005 19 14 2005 2007 2-s2.0-28744438835 10.1096/fj.04-3496fje (Pubitemid 41759746)
34. Natori T., Sata M., Washida M., Hirata Y., Nagai R., Makuuchi M., G-CSF stimulates angiogenesis and promotes tumor growth: Potential contribution of bone marrow-derived endothelial progenitor cells. Biochemical and Biophysical Research Communications 2002 297 4 1058 1061 2-s2.0-0036031829 10.1016/S0006-291X(02)02335-5 (Pubitemid 35230360)
35. Aiello L. P., Avery R. L., Arrigg P. G., Keyt B. A., Jampel H. D., Shah S. T., Pasquale L. R., Thieme H., Iwamoto M. A., Park J. E., Nguyen H. V., Aiello L. M., Ferrara N., King G. L., Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. New England Journal of Medicine 1994 331 22 1480 1487 2-s2.0-0027942607 10.1056/NEJM199412013312203 (Pubitemid 24356306)
36. Banerjee S., Savant V., Scott R. A. H., Curnow S. J., Wallace G. R., Murray P. L., Multiplex bead analysis of vitreous humor of patients with vitreoretinal disorders. Investigative Ophthalmology and Visual Science 2007 48 5 2203 2207 2-s2.0-34250160902 10.1167/iovs.06-1358 (Pubitemid 351261295)
37. Soro-Paavonen A., Watson A. M. D., Li J., Paavonen K., Koitka A., Calkin A. C., Barit D., Coughlan M. T., Drew B. G., Lancaster G. I., Thomas M., Forbes J. M., Nawroth P. P., Bierhaus A., Cooper M. E., Jandeleit-Dahm K. A., Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 2008 57 9 2461 2469 2-s2.0-52749084063 10.2337/db07-1808
38. Li F., Yang N., Zhang L., Tan H., Huang B., Liang Y., Chen M., Yu X., Increased expression of toll-like receptor 2 in rat diabetic nephropathy. American Journal of Nephrology 2010 32 2 179 186 2-s2.0-77954406111 10.1159/000317023
39. Yao D., Brownlee M., Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes 2010 59 1 249 255 2-s2.0-77449142258 10.2337/db09-0801
40. Nin J. W. M., Ferreira I., Schalkwijk C. G., Prins M. H., Chaturvedi N., Fuller J. H., Stehouwer C. D. A., Karamanos B., Sjolie A.-K., Toeller M., Pozza G., Ferriss B., Porta M., Rottiers R., Michel G., Serum high-mobility group box-1 levels are positively associated with micro- and macroalbuminuria but not with cardiovascular disease in type 1 diabetes: The EURODIAB prospective complications study. European Journal of Endocrinology 2012 166 2 325 332 2-s2.0-84856078195 10.1530/EJE-11-0662
41. Mullins G. E., Sunden-Cullberg J., Johansson A. S., Rouhiainen A., Erlandsson-Harris H., Yang H., Tracey K. J., Rauvala H., Palmblad J., Andersson J., Treutiger C. J., Activation of human umbilical vein endothelial cells leads to relocation and release of high-mobility group box chromosomal protein 1. Scandinavian Journal of Immunology 2004 60 6 566 573 2-s2.0-10844281923 10.1111/j.0300-9475.2004.01518.x (Pubitemid 39665101)
42. Martin T. A., Watkins G., Lane J., Jiang W. G., Assessing microvessels and angiogenesis in human breast cancer, using VE-cadherin. Histopathology 2005 46 4 422 430 2-s2.0-17144422869 10.1111/j.1365-2559.2005.02104.x (Pubitemid 40516758)
43. Villasante A., Pacheco A., Ruiz A., Pellicer A., Garcia-Velasco J. A., Vascular endothelial cadherin regulates vascular permeability: Implications for ovarian hyperstimulation syndrome. Journal of Clinical Endocrinology and Metabolism 2007 92 1 314 321 2-s2.0-33846104416 10.1210/jc.2006-1231 (Pubitemid 46067549)
44. Navaratna D., McGuire P. G., Menicucci G., Das A., Proteolytic degradation of VE-cadherin alters the blood-retinal barrier in diabetes. Diabetes 2007 56 9 2380 2387 2-s2.0-34548397756 10.2337/db06-1694 (Pubitemid 47358245)
45. Blázquez-Medela A. M., García-Ortiz L., Gómez-Marcos M. A., Recio-Rodríguez J. I., Sánchez-Rodríguez A., López-Novoa J. M., Martínez-Salgado C., Increased plasma soluble endoglin levels as an indicator of cardiovascular alterations in hypertensive and diabetic patients. BMC Medicine 2010 8 article 86 2-s2.0-78650290584 10.1186/1741-7015-8-86
46. Ikemoto T., Hojo Y., Kondo H., Takahashi N., Hirose M., Nishimura Y., Katsuki T., Shimada K., Kario K., Plasma endoglin as a marker to predict cardiovascular events in patients with chronic coronary artery diseases. Heart and Vessels 2011 27 4 344 351 2-s2.0-79958040114 10.1007/s00380-011-0163-z
47. Abu El-Asrar A. M., Van den Steen P. E., Al-Amro S. A., Missotten L., Opdenakker G., Geboes K., Expression of angiogenic and fibrogenic factors in proliferative vitreoretinal disorders. International Ophthalmology 2007 27 1 11 22 2-s2.0-34247633082 10.1007/s10792-007-9053-x (Pubitemid 46672141)
48. Giebel S. J., Menicucci G., McGuire P. G., Das A., Matrix metalloproteinases in early diabetic retinopathy and their role in alternation of the blood-retinal barrier. Laboratory Investigation 2005 85 5 597 607 2-s2.0-18744362465 10.1038/labinvest.3700251 (Pubitemid 40675441)
49. Venkatesha S., Toporsian M., Lam C., Hanai J. I., Mammoto T., Kim Y. M., Bdolah Y., Lim K. H., Yuan H. T., Libermann T. A., Stillman I. E., Roberts D., D'Amore P. A., Epstein F. H., Sellke F. W., Romero R., Sukhatme V. P., Letarte M., Karumanchi S. A., Soluble endoglin contributes to the pathogenesis of preeclampsia. Nature Medicine 2006 12 6 642 649 2-s2.0-33744985816 10.1038/nm1429 (Pubitemid 43865232)
50. Walshe T. E., Saint-Geniez M., Maharaj A. S. R., Sekiyama E., Maldonado A. E., D'Amore P. A., TGF- β is required for vascular barrier function, endothelial survival and homeostasis of the adult microvasculature. PLoS One 2009 4 4 2-s2.0-64549113715 10.1371/journal.pone.0005149 e5149